Do neomycin and cholestyramine, alone or in combination with clofibrate, reduce plasma cholesterol in patients with primary type II hyperlipoproteinemia?
While neomycin and cholestyramine effectively reduce plasma cholesterol in type II hyperlipoproteinemia, their clinical utility is limited by severe dyspeptic side-effects leading to high discontinuation rates.
Abstract. Thirteen patients with primary type II hyperlipoproteinemia have been treated with neomycin and cholestyramine, alone and in combination with clofibrate, during 6‐week periods in a cross‐over study lasting 36 weeks. Neomycin, 2 g daily, and cholestyramine, 24 g daily, produced significant median 23% and 27% reductions of plasma cholesterol respectively. Cholesterol was further but non‐significantly reduced by addition of clofibrate 2 g daily. Dyspeptic side‐effects were severe, necessitating withdrawal of 7 and 4 patients from treatment with neomycin and cholestyramine respectively.
Ole Færgeman (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: